The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Jens Atzpodien

Fachklinik Hornheide an der Westfälischen Wilhelms-Universität Münster

Dorbaumstr

Münster

Germany

[email]@yahoo.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Fachklinik Hornheide an der Westfälischen Wilhelms-Universität Münster, Dorbaumstr, Münster, Germany. 2003 - 2011
  • Medizinische Hochschule Hannover, Germany. 2002 - 2004
  • European Institute for Tumor Immunology and Prevention (EUTIP), Gotenstr. 152, 53175 Bonn, Germany. 2002

References

  1. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. Atzpodien, J., Terfloth, K., Fluck, M., Reitz, M. Am. J. Clin. Oncol. (2011) [Pubmed]
  2. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients. Atzpodien, J., Morawek, L., Fluck, M., Reitz, M. Cancer Chemother. Pharmacol. (2009) [Pubmed]
  3. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Atzpodien, J., Terfloth, K., Fluck, M., Reitz, M. Cancer Chemother. Pharmacol. (2008) [Pubmed]
  4. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma. Atzpodien, J., Reitz, M. Cancer Biother. Radiopharm. (2008) [Pubmed]
  5. GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Atzpodien, J., Reitz, M. Cancer Biother. Radiopharm. (2007) [Pubmed]
  6. Fractional polynomials in a new metastatic renal carcinoma continuous prognostic index involving histology, laboratory, and clinical predictors. Atzpodien, J., Royston, P., Stoerkel, S., Reitz, M. Cancer Biother. Radiopharm. (2007) [Pubmed]
  7. Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Atzpodien, J., Terfloth, K., Fluck, M., Reitz, M. Br. J. Cancer (2007) [Pubmed]
  8. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien, J., Kirchner, H., Rebmann, U., Soder, M., Gertenbach, U., Siebels, M., Roigas, J., Raschke, R., Salm, S., Schwindl, B., Müller, S.C., Hauser, S., Leiber, C., Huland, E., Heinzer, H., Siemer, S., Metzner, B., Heynemann, H., Fornara, P., Reitz, M. Br. J. Cancer (2006) [Pubmed]
  9. Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients. Atzpodien, J., Reitz, M. Cancer Biother. Radiopharm. (2006) [Pubmed]
  10. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Atzpodien, J., Reitz, M. Cancer Biother. Radiopharm. (2005) [Pubmed]
  11. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma. Atzpodien, J., Wandert, T., Reitz, M. Crit. Rev. Oncol. Hematol. (2005) [Pubmed]
  12. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S.A., Roigas, J., Müller, S.C., Bodenstein, H., Pomer, S., Metzner, B., Rebmann, U., Oberneder, R., Siebels, M., Wandert, T., Puchberger, T., Reitz, M. J. Clin. Oncol. (2004) [Pubmed]
  13. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Atzpodien, J., Fluck, M., Reitz, M. Cancer Biother. Radiopharm. (2004) [Pubmed]
  14. Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Atzpodien, J., Küchler, T., Wandert, T., Reitz, M. Br. J. Cancer (2003) [Pubmed]
  15. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Atzpodien, J., Neuber, K., Kamanabrou, D., Fluck, M., Bröcker, E.B., Neumann, C., Rünger, T.M., Schuler, G., von den Driesch, P., Müller, I., Paul, E., Patzelt, T., Reitz, M. Br. J. Cancer (2002) [Pubmed]
  16. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Atzpodien, J., Hoffmann, R., Franzke, M., Stief, C., Wandert, T., Reitz, M. Cancer (2002) [Pubmed]
 
WikiGenes - Universities